-
1.发明授权Stem cells of the islets of Langerhans and their use in treating diabetes mellitus 有权朗格汉斯胰岛的干细胞及其在治疗糖尿病中的应用公开(公告)号：US07544510B2
公开(公告)日：2009-06-09
申请号：US11410412
申请日：2006-04-24
CPC分类号： C12N5/0676 , A01K67/0271 , A61K35/12 , A61K2035/122 , C12N5/0677 , C12N5/0678 , C12N2500/34 , C12N2501/11 , C12N2501/115 , C12N2501/335 , C12N2510/02
摘要： Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
摘要翻译： 描述了用于治疗I型胰岛素依赖性糖尿病和其它条件的方法和组合物，其使用能够分化成多种胰岛细胞（包括产生胰岛素的β细胞）以及肝细胞的新鉴定的干细胞。 巢蛋白已被鉴定为胰腺干细胞的分子标记，而细胞角蛋白-19可作为不同类别的胰岛导管细胞的标记物。 描述了方法，其中可以从胰岛中分离巢蛋白阳性干细胞并进行培养，以获得进一步的干细胞或假胰岛样结构。 公开了胰腺干细胞离体分化方法。 描述了方法，其中胰腺干细胞可以被分离，扩增和移植到有需要的患者中，同种异体地，异质性或异质性的，以提供丢失或损伤的胰岛素分泌细胞或其他细胞的替代。
-
2.发明申请Methods For Cell Culture Using A Synthetic, Defined Collagen Mimetic Surface 审中-公开使用合成，定义的胶原模拟表面的细胞培养方法公开(公告)号：US20120149114A1
公开(公告)日：2012-06-14
申请号：US13310988
申请日：2011-12-05
CPC分类号： C12N5/0068 , C12N2533/54
摘要： The present invention discloses methods for enhancing cell attachment, cell proliferation and cell function using a surface which mimics a collagen coated surface. Advantageously, such methods employ a xeno-free, synthetic, chemically defined surface.
摘要翻译： 本发明公开了使用模拟胶原涂层表面的表面增强细胞附着，细胞增殖和细胞功能的方法。 有利地，这种方法采用无异种素，合成的，化学上限定的表面。
-
3.发明授权Stem cells of the islets of langerhans and their use in treating diabetes mellitus 有权朗格汉斯胰岛的干细胞及其在治疗糖尿病中的应用公开(公告)号：US08110399B2
公开(公告)日：2012-02-07
申请号：US11438790
申请日：2006-05-22
申请人： Joel F. Habener , Henryk Zulewski , Melissa K. Thomas , Elizabeth J. Abraham , Mario Vallejo , Colin A. Leech , Anna Louise Nolan , Andreas Lechner
发明人： Joel F. Habener , Henryk Zulewski , Melissa K. Thomas , Elizabeth J. Abraham , Mario Vallejo , Colin A. Leech , Anna Louise Nolan , Andreas Lechner
CPC分类号： A01K67/0271 , A61K35/12 , A61K2035/122 , C12N5/0678 , C12N2500/34 , C12N2501/11 , C12N2501/115 , C12N2501/335 , C12N2510/02
摘要： Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
摘要翻译： 描述了用于治疗I型胰岛素依赖性糖尿病和其它条件的方法和组合物，其使用能够分化成多种胰岛细胞（包括产生胰岛素的β细胞）以及肝细胞的新鉴定的干细胞。 Nestin和ABCG2已被鉴定为胰干细胞的分子标记，而细胞角蛋白-19可作为不同类型的胰岛导管细胞的标记物。 描述了方法，其中可以从胰岛中分离巢蛋白和/或ABCG2-阳性干细胞并进行培养以获得进一步的干细胞或假胰岛样结构。 公开了胰腺干细胞离体分化方法。 描述了方法，其中胰腺干细胞可以被分离，扩增和移植到有需要的患者中，同种异体地，异质性或异质性的，以提供丢失或损伤的胰岛素分泌细胞或其他细胞的替代。
-
公开(公告)号：US07438902B2
公开(公告)日：2008-10-21
申请号：US10984645
申请日：2004-11-09
申请人： Joel E. Habener , Henryk Zulewski , Elizabeth J. Abraham , Mario Vallejo , Denise L. Faustman , Melissa K. Thomas
发明人： Joel E. Habener , Henryk Zulewski , Elizabeth J. Abraham , Mario Vallejo , Denise L. Faustman , Melissa K. Thomas
CPC分类号： C12N5/0676 , A01K67/0271 , A61K35/12 , A61K2035/122 , C12N5/0677 , C12N5/0678 , C12N2500/34 , C12N2501/11 , C12N2501/115 , C12N2501/335 , C12N2510/02
摘要： Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
摘要翻译： 描述了用于治疗I型胰岛素依赖性糖尿病和其它条件的方法和组合物，其使用能够分化成多种胰岛细胞（包括产生胰岛素的β细胞）以及肝细胞的新鉴定的干细胞。 巢蛋白已被鉴定为胰腺干细胞的分子标记，而细胞角蛋白-19可作为不同类别的胰岛导管细胞的标记物。 描述了方法，其中可以从胰岛中分离巢蛋白阳性干细胞并培养以获得进一步的干细胞或假胰岛样结构。 公开了胰腺干细胞离体分化方法。 描述了方法，其中胰腺干细胞可以被分离，扩增和移植到有需要的患者中，同种异体地，异质性或异质性的，以提供丢失或损伤的胰岛素分泌细胞或其他细胞的替代。
-
公开(公告)号：US07537756B2
公开(公告)日：2009-05-26
申请号：US11132687
申请日：2005-05-19
申请人： Joel E. Habener , Hendrik Zulewski , Elizabeth J. Abraham , Mario Vallejo , Denise L. Faustman , Melissa K. Thomas
发明人： Joel E. Habener , Hendrik Zulewski , Elizabeth J. Abraham , Mario Vallejo , Denise L. Faustman , Melissa K. Thomas
CPC分类号： C12N5/0676 , A01K67/0271 , A61K35/12 , A61K2035/122 , C12N5/0677 , C12N5/0678 , C12N2500/34 , C12N2501/11 , C12N2501/115 , C12N2501/335 , C12N2510/02
摘要： Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
摘要翻译： 描述了用于治疗I型胰岛素依赖性糖尿病和其它条件的方法和组合物，其使用能够分化成多种胰岛细胞（包括产生胰岛素的β细胞）以及肝细胞的新鉴定的干细胞。 巢蛋白已被鉴定为胰腺干细胞的分子标记，而细胞角蛋白-19可作为不同类别的胰岛导管细胞的标记物。 描述了方法，其中可以从胰岛中分离巢蛋白阳性干细胞并培养以获得进一步的干细胞或假胰岛样结构。 公开了胰腺干细胞离体分化方法。 描述了方法，其中胰腺干细胞可以被分离，扩增和移植到有需要的患者中，同种异体地，异质性或异质性的，以提供丢失或损伤的胰岛素分泌细胞或其他细胞的替代。
-
6.发明授权Method of pre-inducing a state of immune tolerance before organ transplantation 有权器官移植前预先诱导免疫耐受状态的方法公开(公告)号：US06923959B2
公开(公告)日：2005-08-02
申请号：US10136891
申请日：2002-05-02
申请人： Joel F. Habener , Henryk Zulewski , Elizabeth J. Abraham , Mario Vallejo , Denise L. Faustman , Melissa K. Thomas
发明人： Joel F. Habener , Henryk Zulewski , Elizabeth J. Abraham , Mario Vallejo , Denise L. Faustman , Melissa K. Thomas
IPC分类号： C12N15/09 , A01K67/027 , A61K20060101 , A61K31/436 , A61K31/7088 , A61K35/12 , A61K35/39 , A61K38/00 , A61K38/22 , A61K39/395 , A61K45/00 , A61K48/00 , A61P3/10 , A61P37/06 , A61P43/00 , C12N20060101 , C12N5/02 , C12N5/071 , C12N5/074 , C12Q1/00 , G01N33/53 , C12N5/00
CPC分类号： C12N5/0676 , A01K67/0271 , A61K35/12 , A61K2035/122 , C12N5/0677 , C12N5/0678 , C12N2500/34 , C12N2501/11 , C12N2501/115 , C12N2501/335 , C12N2510/02
摘要： Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
摘要翻译： 描述了用于治疗I型胰岛素依赖性糖尿病和其它条件的方法和组合物，其使用能够分化成多种胰岛细胞（包括产生胰岛素的β细胞）以及肝细胞的新鉴定的干细胞。 巢蛋白已被鉴定为胰腺干细胞的分子标记，而细胞角蛋白-19可作为不同类别的胰岛导管细胞的标记物。 描述了方法，其中可以从胰岛中分离巢蛋白阳性干细胞并培养以获得进一步的干细胞或假胰岛样结构。 公开了胰腺干细胞离体分化方法。 描述了方法，其中胰腺干细胞可以被分离，扩增和移植到有需要的患者中，同种异体地，异质性或异质性的，以提供丢失或损伤的胰岛素分泌细胞或其他细胞的替代。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.018 秒)
